Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental cancer drugs
Birabresib
Другие языки:

    Birabresib

    Подписчиков: 0, рейтинг: 0
    Birabresib
    Birabresib.svg
    Legal status
    Legal status
    • Investigational
    Identifiers
    • 2-[(6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f] [1,2,4]triazolo[4,3-a] [1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    KEGG
    Chemical and physical data
    Formula C25H22ClN5O2S
    Molar mass 491.99 g·mol−1
    3D model (JSmol)
    • CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)NC4=CC=C(C=C4)O)C5=CC=C(C=C5)Cl)C
    • InChI=1S/C25H22ClN5O2S/c1-13-14(2)34-25-22(13)23(16-4-6-17(26)7-5-16)28-20(24-30-29-15(3)31(24)25)12-21(33)27-18-8-10-19(32)11-9-18/h4-11,20,32H,12H2,1-3H3,(H,27,33)/t20-/m0/s1
    • Key:GNMUEVRJHCWKTO-FQEVSTJZSA-N

    Birabresib (OTX-015, MK-8628) is an experimental small molecule inhibitor of BRD2, BRD3, and BRD4 under investigation for the treatment of cancer. It is in development by Merck & Co. It is currently in clinical trials for leukemia and glioblastoma.


    Новое сообщение